Skip to main content
. 2020 Dec 19;23:629–639. doi: 10.1016/j.omtn.2020.12.012

Figure 2.

Figure 2

Transfer of the DYS-HAC2 into DMD-derived human iPSCs for gene and cell therapy

(A) Multiplex genomic PCR results of DMD iPSCs carrying the DYS-HAC2. (B) Representative karyotype analysis of DMD-iPSCs with the DYS-HAC2. (C) FISH image of metaphase of DMD iPSCs with the DYS-HAC2. Yellow arrow indicates the DYS-HAC2 and the inset shows enlarged image. Red arrows indicate the endogenous centromeres of human chromosomes 13 and 21. (D) Gene expression analyses by RT-PCR of pluripotency marker genes REX1, NANOG, OCT4, and SOX2. (E) Representative images of the teratoma formation assay of DMD-iPSCs carrying the DYS-HAC2.